Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy.
age-related macular degeneration
anti-VEGFs
diabetic retinopathy
pharmacovigilance
ranibizumab
retrospective study
Journal
Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
ppublish
Résumé
The aged population is constantly growing, thus fostering an increase in age-dependent diseases. Among these, diabetic retinopathy (DR) along with age-related macular degeneration entails progressive vision loss. Since such conditions are associated with the proliferation of novel vessels, their pharmacotherapeutic management consists of the intravitreal injection of anti-vascular endothelial growth factor drugs, able to hinder the driving of vascular proliferation prompted by vascular endothelial growth factor. The humanized anti-vascular endothelial growth factor monoclonal antibody ranibizumab provided evidence for efficacy in several trials, hence earning approval by the US Food and Drug Administration for therapeutic use in all the stages of DR. Due to the lack of epidemiologic and pharmacoeconomic evaluation in the local Calabria Region context, the present retrospective observational study focused on prevalence of DR and age-related macular degeneration, treatment and cost of therapy with ranibizumab in 870 patients arriving to clinical observation at the "Mater Domini" University Hospital in Calabria, Italy from January 2014 to June 2017. Data were extracted from the database of ophthalmology ward and subjected to statistical analysis. The results suggest that the most frequent retinal diseases are age-related macular degeneration and DR and that the use of ranibizumab has been decreasing over the 4-year study period together with the associated cost per patient which was similar for both disorders. Therefore, appropriateness of treatment with drugs other than ranibizumab needs to be assessed in this setting and deep monitoring of pharmacologic treatment for retinal diseases is necessary to prevent or delay visual acuity decrease and complete vision loss. Study procedures were performed in accordance with the "Mater Domini" University Hospital ethical standards of the responsible committee on human experimentation.
Identifiants
pubmed: 30964071
pii: NeuralRegenRes_2019_14_8_1445_253528
doi: 10.4103/1673-5374.253528
pmc: PMC6524505
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1445-1448Déclaration de conflit d'intérêts
None
Références
Drugs Aging. 2002;19(2):101-33
pubmed: 11950377
Invest Ophthalmol Vis Sci. 2003 May;44(5):2155-62
pubmed: 12714656
Diabetologia. 2005 Jul;48(7):1300-6
pubmed: 15918015
Diabet Med. 2007 Sep;24(9):969-76
pubmed: 17593241
Ophthalmology. 2010 Feb;117(2):313-9.e1
pubmed: 20022117
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Ophthalmic Epidemiol. 2011 Jun;18(3):129-36
pubmed: 21609241
Clin Ophthalmol. 2011;5:771-81
pubmed: 21750610
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Curr Diab Rep. 2012 Aug;12(4):346-54
pubmed: 22585044
Indian J Ophthalmol. 2012 Sep-Oct;60(5):428-31
pubmed: 22944754
J Ophthalmol. 2012;2012:723169
pubmed: 23097691
J Diabetes Res. 2016;2016:3627465
pubmed: 27990441
Eye Vis (Lond). 2016 Dec 22;3:34
pubmed: 28032115
J Diabetes Complications. 2017 Aug;31(8):1348-1353
pubmed: 28551296
Cochrane Database Syst Rev. 2017 Jun 22;6:CD007419
pubmed: 28639415
Ophthalmology. 2017 Dec;124(12):1753-1763
pubmed: 28712657
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):493-497
pubmed: 28906084
Acta Ophthalmol. 2018 Feb;96 Suppl A109:1-46
pubmed: 29468838
J Manag Care Spec Pharm. 2018 Jul;24(7):608-616
pubmed: 29952707
Int J Endocrinol. 2018 Jul 5;2018:9254126
pubmed: 30123269
Drugs Context. 2018 Aug 13;7:212532
pubmed: 30181760
Arch Ophthalmol. 1995 Dec;113(12):1538-44
pubmed: 7487623